Experimental antibody aims to shield hearts after stent treatment
NCT ID NCT06678074
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a monoclonal antibody called atibuclimab (IC14) in 10 adults who had a severe heart attack (STEMI) and received a stent. The drug is given by IV to see if it can prevent further heart muscle damage and reduce inflammation. Participants are compared to those receiving a placebo to check safety and heart function improvements.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STEMI are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Virginia
Charlottesville, Virginia, 22908-1394, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new CT scan see brain stents clearly enough to replace an invasive test?
- Insulin resistance may predict poor blood flow after heart attack stenting in diabetics
- Could dropping aspirin early after stent surgery be safer?
- Heart attack aftermath: which treatment causes less internal bleeding?
- Sound waves vs X-Rays: which guides heart stents better?
- Can a chinese herbal tablet help hearts heal after a heart attack?